CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 93 filers reported holding CONCERT PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,000 | -85.7% | 239 | -89.4% | 0.00% | – |
| Q4 2021 | $7,000 | -22.2% | 2,264 | -14.7% | 0.00% | – |
| Q3 2021 | $9,000 | -18.2% | 2,653 | -0.1% | 0.00% | – |
| Q2 2021 | $11,000 | +450.0% | 2,656 | +2131.9% | 0.00% | – |
| Q4 2020 | $2,000 | +100.0% | 119 | +29.3% | 0.00% | – |
| Q3 2020 | $1,000 | -96.6% | 92 | -96.8% | 0.00% | – |
| Q2 2020 | $29,000 | +93.3% | 2,901 | +181.7% | 0.00% | – |
| Q3 2018 | $15,000 | -97.3% | 1,030 | -96.9% | 0.00% | -100.0% |
| Q2 2018 | $560,000 | -25.5% | 33,261 | +1.3% | 0.00% | 0.0% |
| Q1 2018 | $752,000 | +32.6% | 32,821 | +49.7% | 0.00% | 0.0% |
| Q4 2017 | $567,000 | +18800.0% | 21,923 | +10861.5% | 0.00% | – |
| Q1 2017 | $3,000 | +50.0% | 200 | +78.6% | 0.00% | – |
| Q4 2015 | $2,000 | -81.8% | 112 | -84.2% | 0.00% | – |
| Q2 2015 | $11,000 | 0.0% | 709 | 0.0% | 0.00% | – |
| Q1 2015 | $11,000 | 0.0% | 709 | -14.1% | 0.00% | – |
| Q4 2014 | $11,000 | – | 825 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| L1 Capital Pty Ltd | 1,050,124 | $10,312,000 | 3.31% |
| Alambic Investment Management, L.P. | 19,934 | $196,000 | 2.15% |
| INGALLS & SNYDER LLC | 1,363,603 | $13,391,000 | 0.92% |
| ACUTA CAPITAL PARTNERS, LLC | 300,000 | $2,946,000 | 0.80% |
| RA Capital Management | 1,858,474 | $18,250,000 | 0.33% |
| Perceptive Advisors | 2,150,641 | $21,119,000 | 0.31% |
| SPHERA FUNDS MANAGEMENT LTD. | 310,000 | $3,044,000 | 0.30% |
| Eversept Partners, LP | 103,829 | $1,019,601 | 0.23% |
| Opaleye Management Inc. | 100,000 | $982,000 | 0.19% |
| GSA CAPITAL PARTNERS LLP | 58,095 | $570,000 | 0.10% |